OTHER-RARE-DISEASE-TOPICS

RARE-DISEASE

The Stigma of Rare Diseases

<h3>Summary of the Presentation:&nbsp;</h3>
In this video, Prof. Tawfeg Ben Omran speaks about how to ease the acceptance of LSDs in our society and how stigma could impact diagnosis of patients or even, impact compliance/adherence to therapy.

Short Biography of the speaker:
Dr. Tawfeg Ben Omran (Qatar)
Senior consultant and Head of Clinical and Metabolic Genetics at Hamad Medical Corporation, Qatar.
Associate Professor at Weill Cornell Medical College, Qatar &amp; New York-USA.

POMPE

Social stigma

Individuals with rare diseases are usually socially isolated and excluded by friends and relatives, having less chance for employment. Social Stigma consider as one of the main barriers that stop many of LSD patients either to be identified or treated cause such diseases have a huge impact on patient’s lives. In this video Dr. Tawfeg will discuss the challenges and social stigma related to rare diseases including LSDs and how can we solve them.

<h2>Dr. Tawfeg Ben Omran Biography:</h2>
Dr. Ben-Omran received his speciality training in clinical &amp; metabolic genetics at the Hospital for Sick Children, University of Toronto, Canada. He has obtained both FRCPS &amp; FCCMG in Medical Genetics in 2006. Currently, he is a senior consultant and Head of Clinical and Metabolic Genetics at Hamad Medical Corporation. He is an Associate Professor at Weill Cornell Medical College, Qatar &amp; New York-USA. He is also a Distinguished Visiting Scientist at Boston Children’s Hospital-USA.
He contributes to the body of published knowledge in clinical and metabolic genetics, with over 60 published articles in peer reviewed journals, book chapters and abstracts. He is reviewer for many clinical genetics journals.
He is an active clinical researcher, collaborating on projects with local, regional &amp; international communities. He is a lead primary investigator in many high profile research projects &amp; clinical trials to evaluate the long-term effects of enzyme replacement therapy in patients with different lysosomal storage disorders. His main scientific interests include genetics of brain malformation&amp; microcephaly, white matter disorders, dysmorphology, autosomal recessive disorders. In addition, Dr. Ben-Omran is an external advisor and expert for E-HOD (European registry and network for homocystinurias and methylation defects).
He is recognized as an expert in genetic disorders of the Arab population. His national &amp; international presence is clear. In 2013, he received the "Princess Aljawhara Center Award for The Best Research in Basic Genetics" the most competitive &amp; prestigious awards. He received Research Award from MRC-HMC for Homocystinuria project and Stars of Excellence Award 2011 for both Pioneering Newborn Screening &amp; specialized care of Genetic Diseases in the Middle East. Recently, awarded the Stars of Excellence in research 2014: Cutting Edge of Research in Medical Genetics.
He has memberships in many societies including: American Society of Human Genetics, European Society of Human Genetics, Society for the Study of Inborn Errors of Metabolism, Middle East Metabolic Genetic Group, the Middle East &amp; North Africa Newborn Screening Initiative, Middle Eastern Lysosomal Storage Diseases Expert Council Advisory Board, Child Health Research Advisory Committee, International Society for Prenatal Diagnosis, Chairman of Middle East Metabolic Dieticians Group &amp; Founder Member &amp; Regional Representative of SSIEM Adult Metabolic Physicians Group.

Multidisciplinary approaches in Rare Disease Patient management

Summary of the Presentation:&nbsp;
Interviewed by Dr. Nawal Makhseed, Ms. Amal tolba, the Founder and managing director of HOPE AMC, Dubai, UAE speaks about what the rehabilitation setup should include to succeed.

Short Biography of the speaker:
Ms. Amal Tolba (UAE)
Founder of the UAE Special needs support group.
Founder and managing director of HOPE AMC, Dubai, UAE.
A proud mom of child with special needs.

Multidisciplinary approaches in Rare Disease Patient management in KSA

Short Biography of the speaker:
Ms. Wijdan Ahmed (KSA)
Advanced Clinical Specialist and Team Manager, Medical Genetics Clinic, King Faisal Specialist Hospital and Research Centre, KSA.

Lysosomal Storage Diseases from Neurology Perspective

In this video, Dr. Dina Saleh is sharing information about lysosomal storage diseases but this time, it is from neurologist perspective.

LSDs overview

Summary of the Presentation:&nbsp;
LSDs are a diverse group of diseases result from enzyme deficiencies lead to defects in lysosomal function. There are more than 50 inherited LSDs, collective incidence as high as 1:4000. Mostly inherited as autosomal recessive, thus LSDs are more prevalent in consanguineous populations. Early diagnosis is important to start the treatment and prevent complications. In this video Dr. Tawfeg will discuss the diagnosis and management of LSD, including how to recognize the common red flag symptoms and signs of LSDs.
In this video, Prof. Tawfeg Ben Omran discusses how could we diagnose and manage the lysosomal storage disorders (LSDs)

Short Biography of the speaker:
Dr. Tawfeg Ben Omran Biography:
Dr. Ben-Omran received his speciality training in clinical &amp; metabolic genetics at the Hospital for Sick Children, University of Toronto, Canada. He has obtained both FRCPS &amp; FCCMG in Medical Genetics in 2006. Currently, he is a senior consultant and Head of Clinical and Metabolic Genetics at Hamad Medical Corporation. He is an Associate Professor at Weill Cornell Medical College, Qatar &amp; New York-USA. He is also a Distinguished Visiting Scientist at Boston Children’s Hospital-USA.
He contributes to the body of published knowledge in clinical and metabolic genetics, with over 60 published articles in peer reviewed journals, book chapters and abstracts. He is reviewer for many clinical genetics journals.
He is an active clinical researcher, collaborating on projects with local, regional &amp; international communities. He is a lead primary investigator in many high profile research projects &amp; clinical trials to evaluate the long-term effects of enzyme replacement therapy in patients with different lysosomal storage disorders. His main scientific interests include genetics of brain malformation&amp; microcephaly, white matter disorders, dysmorphology, autosomal recessive disorders. In addition, Dr. Ben-Omran is an external advisor and expert for E-HOD (European registry and network for homocystinurias and methylation defects).
He is recognized as an expert in genetic disorders of the Arab population. His national &amp; international presence is clear. In 2013, he received the "Princess Aljawhara Center Award for The Best Research in Basic Genetics" the most competitive &amp; prestigious awards. He received Research Award from MRC-HMC for Homocystinuria project and Stars of Excellence Award 2011 for both Pioneering Newborn Screening &amp; specialized care of Genetic Diseases in the Middle East. Recently, awarded the Stars of Excellence in research 2014: Cutting Edge of Research in Medical Genetics.
He has memberships in many societies including: American Society of Human Genetics, European Society of Human Genetics, Society for the Study of Inborn Errors of Metabolism, Middle East Metabolic Genetic Group, the Middle East &amp; North Africa Newborn Screening Initiative, Middle Eastern Lysosomal Storage Diseases Expert Council Advisory Board, Child Health Research Advisory Committee, International Society for Prenatal Diagnosis, Chairman of Middle East Metabolic Dieticians Group &amp; Founder Member &amp; Regional Representative of SSIEM Adult Metabolic Physicians Group.

IOPD Challenges

Dr. Nadia AlHashmi, metabolic and clinical genetic consultant at child health department of Royal Hospital, Muscat, Oman, is sharing a real experience of the journey of one of her IOPD patients, starting with early manifestations and suffering, through different challenges of diagnosis and management, till current status and case progression, giving some key learnings for better management of IOPD and a hope for a better life for all IOPD patients.

<h2>ASMD types A/B and B: Manifestations progress less rapidly than in type A and may include any combination of the following1</h2>
Hepatomegaly is seen in &gt;70% of patients1,2* 
 Symptoms of hepatomegaly include enlarged abdomen and abdominal pain1,3

<ul>
 <li>Hepatomegaly</li>
 <li>Fibrosis and cirrhosis</li>
 <li>Dyslipidemia</li>
</ul>

LIVER

black

<ul>
 <li>Severe abnormalities (cognitive impairment, loss of motor function, etc)</li>
 <li>Hypotonia/hyporeflexia</li>
</ul>

NEUROLOGIC

<ul>
 <li>Splenomegaly (can be up to 30 times normal size)</li>
 <li>Pain, pressure, and early satiety due to enlarged spleen</li>
</ul>

SPLEEN

<ul>
 <li>Coronary artery or heart valve disease</li>
</ul>

CARDIAC

<ul>
 <li>Interstitial lung disease (ILD)</li>
 <li>Respiratory infections, including pneumonia</li>
 <li>Shortness of breath and chronic fatigue</li>
</ul>

LUNGS

<ul>
 <li>Back, limb, and/or joint pain</li>
 <li>Pathologic fractures</li>
 <li>Osteopenia</li>
 <li>Osteoporosis in adults</li>
</ul>

SKELETAL

<ul>
 <li>Thrombocytopenia</li>
 <li>Excessive bleeding and easy bruising</li>
 <li>Anemia</li>
 <li>Leukopenia</li>
</ul>

HEMATOLOGIC

<ul>
 <li>Growth delay and puberty delay in adolescents, with adult heights in the low-normal range</li>
 <li>Excessive bleeding and easy bruising</li>
 <li>Delays in reaching developmental milestones in children</li>
 <li>Learning disabilities, changes in behavior, and/or loss of mobility and coordination</li>
</ul>

GROWTH AND DEVELOPMENT

*Symptom prevalence data for hepatomegaly is only for patients with ASMD type B.

References

Potential Hepatic Manifestations of ASMD Often Overlap&nbsp;With Hepatic Disorders and Other&nbsp;Lysosomal Storage&nbsp;Diseases1&nbsp;
<table border="1" cellpadding="1" cellspacing="1" style="width:100%;">
 <tbody>
 <tr>
 <td style="width: 20%;">Potential hepatic symptoms of ASMD</td>
 <td style="text-align: center; width: 18%;">Hepatomegaly</td>
 <td style="text-align: center; width: 16%;">Elevated hepatic enzymes</td>
 <td style="text-align: center; width: 15%;">Fibrosis/ 
 cirrhosis</td>
 <td style="text-align: center; width: 15%;">Hepatic failure</td>
 <td style="text-align: center; width: 16%;">Portal hypertension</td>
 </tr>
 <tr>
 <td style="width: 20%;">ASMD1</td>
 <td style="width: 18%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 </tr>
 <tr>
 <td style="width: 20%;">Chronic hepatitis B1-3</td>
 <td style="width: 18%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 </tr>
 <tr>
 <td style="width: 20%;">Nonalcoholic fatty liver disease4,5</td>
 <td style="width: 18%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 </tr>
 <tr>
 <td style="width: 20%;">Cryptogenic cirrhosis1,6,7</td>
 <td style="width: 18%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔*</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 </tr>
 <tr>
 <td style="width: 20%;">Niemann-Pick disease type C1,8,9</td>
 <td style="width: 18%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 </tr>
 <tr>
 <td style="width: 20%;">Lysosomal acid lipase deficiency1,10,11&nbsp;</td>
 <td style="width: 18%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 </tr>
 <tr>
 <td style="width: 20%;">Gaucher disease1,12,13</td>
 <td style="width: 18%; text-align: center;">✔</td>
 <td style="width: 16%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔</td>
 <td style="width: 15%; text-align: center;">✔†</td>
 <td style="width: 16%; text-align: center;">✔</td>
 </tr>
 </tbody>
</table>
*Aminotransferase levels, such as AST and ALT, are typically only mildly elevated or normal in those with cryptogenic cirrhosis.6 †Development of end-stage liver disease is rare with Gaucher disease and tends to include the associated complications of hepatic decompensation.12 
 ALT=alanine aminotransferase; ASMD=acid sphingomyelinase deficiency; AST=aspartate aminotransferase.

What Are the Signs and Symptoms of ASMD?

ACID-SPHINGOMYLENASE-DEFICIENCY-NIEMANN-PICK

Welcome to UNCOVER ASMD GAUCHER podcast series where we talk about typical diagnosis of patient journey, challenges facing, new diagnostic technologies, effective ways to support patients and families and social stigma

<h3>Episode 1: ASMD &amp; Gaucher Disease</h3>
Listen to Dr. Nuha AlZaabi 
 Metabolic geneticist consultant-Fujairah Hospital, EHS. UAE

Uncover ASMD and GAUCHER

<h3>Episode 2: Similarities and Differences between Gaucher &amp; ASMD</h3>
Listen to Dr. Nuha AlZaabi 
 Metabolic geneticist consultant-Fujairah Hospital, EHS. UAE

<h3>Episode 3: Challenges in diagnosing of Gaucher and ASMD</h3>
Listen to Dr. Nuha AlZaabi 
 Metabolic geneticist consultant-Fujairah Hospital, EHS. UAE

<h3>Episode 4: Management of ASMD Gaucher Disease</h3>
Listen to Dr. Nuha AlZaabi 
 Metabolic geneticist consultant-Fujairah Hospital, EHS. UAE

<h3>Episode 5: Gaucher and ASMD from the patient`s eyes</h3>
Listen to Dr. Nuha AlZaabi 
 Metabolic geneticist consultant-Fujairah Hospital, EHS. UAE

<h3>Episode 6: Raising Awareness and Education and the role of the society</h3>
Listen to Dr. Nuha AlZaabi 
 Metabolic geneticist consultant-Fujairah Hospital, EHS. UAE

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Articles